Erster Deutscher Hanf Aktienfonds

DGAP-News: Biotest AG: Biotest AG takes next step in developing a new haemophilia therapeutic to target patient needs

Nachricht vom 04.12.2018 (www.4investors.de) -


DGAP-News: Biotest AG / Key word(s): Research Update

Biotest AG: Biotest AG takes next step in developing a new haemophilia therapeutic to target patient needs
04.12.2018 / 07:00


The issuer is solely responsible for the content of this announcement.
PRESS RELEASE

Biotest AG takes next step in developing a new haemophilia therapeutic to target patient needs

- Biotest exercises its option and receives exclusive rights for haemophilia on the use of Affibody's Albumod(TM) technology designed to prolong the half life of biopharmaceuticals

- Preclinical results suggest a high probability of success for improving properties of innovative new biopharmaceuticals in haemophilia

Dreieich, 4 December 2018. Biotest AG today announces to have finalized the research phase of the research license and option agreement signed in 2015 and decided to exercise its option. Biotest will receive exclusive rights for further development and commercialization of its innovative new haemophilia product.

"Preclinical results so far with the Albumod(TM) technology are very promising and we believe in its potential for the development of improved protein drugs in Biotest's therapeutic areas such as haemophilia" says Dr Jörg Schüttrumpf, Senior Vice President Global Research Biotest.

Affibody will receive a license conversion fee and milestone payments as well as royalties.

About haemophilia
As a lifelong inherited bleeding disorder, haemophilia affects about 1 in 10,000 people worldwide. With estimated USD 11 billion in 2024, the global FVIII/FIX market is substantial and grows with a compound annual growth rate (CAGR) of around 1.8%. Haemophilia is one of a number of such disorders that prevent blood from clotting properly. People with haemophilia experience prolonged internal bleeding that can result from a seemingly minor injury. Bleeding into joints and muscles causes severe pain and disability while bleeding into major organs, such as the brain, can cause death. For more information on haemophilia, please visit the World Federation of Haemophilia website at http://www.wfh.org/en/page.aspx?pid=646

About the AlbumodTM platform
Affibody's AlbumodTM technology is designed to enhance the efficacy of biopharmaceuticals by extending their circulatory half-life, thereby allowing for less frequent dosing and less fluctuations of concentrations in blood. In addition to these patient benefits, the overall treatment costs could be reduced. For more information please refer to: www.affibody.se.About Affibody AB
Affibody AB is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody(R) molecules and AlbumodTM. Affibody is developing a portfolio of innovative drug projects and in addition, offers the half-life extension technology, AlbumodTM for outlicensing.

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition, Biotest develops monoclonal antibodies in certain cancer indications and in systemic lupus erythematodes, an autoimmune disease, which are produced by recombinant technologies. Biotest has more than 1,600 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.IR contact
Dr Monika Buttkereit
Phone: +49-6103-801-4406
Mail: investor_relations@biotest.de

PR contact
Dirk Neumüller
Phone: +49-6103-801-269
Mail: pr@biotest.com
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.












04.12.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language:
English
Company:
Biotest AG

Landsteinerstraße 5

63303 Dreieich


Germany
Phone:
0 61 03 - 8 01-0
Fax:
0 61 03 - 8 01-150
E-mail:
investor_relations@biotest.de
Internet:
http://www.biotest.de
ISIN:
DE0005227235, DE0005227201
WKN:
522723, 522720
Listed:
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange

 
End of News
DGAP News Service




753839  04.12.2018 







Aktuelle Nachrichten aus der 4investors-Redaktion

19.12.2018 - BYD Aktie: Das könnte knapp werden
19.12.2018 - Evotec: Rettet ein Interview die Aktie vor dem Verkaufssignal?
19.12.2018 - RIB Software Aktie: War das der Start der Aufholjagd?
19.12.2018 - Gazprom Aktie: Die Lage steht auf der Kippe
19.12.2018 - Steinhoff Aktie: Was war denn hier los?
18.12.2018 - Klassik Radio: Auf Rekordkurs – neue Prognose
18.12.2018 - USU Software senkt Prognose aufgrund von Projektverzögerungen
18.12.2018 - Aurelius Aktie: Raus aus dem Keller…
18.12.2018 - BASF Aktie: Realisieren sich die Breakchancen noch?
18.12.2018 - Bayer: Neuer Milliarden-Kredit


Chartanalysen

19.12.2018 - BYD Aktie: Das könnte knapp werden
19.12.2018 - RIB Software Aktie: War das der Start der Aufholjagd?
19.12.2018 - Gazprom Aktie: Die Lage steht auf der Kippe
19.12.2018 - Steinhoff Aktie: Was war denn hier los?
18.12.2018 - Aurelius Aktie: Raus aus dem Keller…
18.12.2018 - BASF Aktie: Realisieren sich die Breakchancen noch?
18.12.2018 - Osram Aktie: Wichtige Signale aus der technischen Analyse
18.12.2018 - SGL Carbon Aktie: Hohe Potenziale im Breakfall!
18.12.2018 - Heidelberger Druck Aktie: Geht die Talfahrt weiter, oder passiert hier was?
18.12.2018 - ISRA Vision Aktie im Crashmodus: Ausverkauf beendet?


Analystenschätzungen

18.12.2018 - E.On Aktie: Probleme durch geplatzten innogy-Deal?
18.12.2018 - RIB Software Aktie: Drastische Reaktion
18.12.2018 - Lufthansa: Nach der Pleite von Air Berlin
18.12.2018 - Tele Columbus: Fast ein Verdopplungspotenzial
18.12.2018 - M1 Kliniken: Coverage wird aufgenommen
18.12.2018 - Wirecard: Eine aussichtsreiche Aktie
18.12.2018 - Freenet: Interessanter Sektor
18.12.2018 - Innogy: Kurs liegt über Kursziel der Aktie
18.12.2018 - Nordex: Ein kurzer Aufschwung
18.12.2018 - E.On: Nach der Innogy-News


Kolumnen

19.12.2018 - USA: Baugenehmigungen steigen infolge von Wiederaufbaumaßnahmen - Commerzbank Kolumne
19.12.2018 - EuroStoxx50: Bullen wieder mächtig unter Druck - UBS Kolumne
19.12.2018 - DAX: Keine neuen Impulse - UBS Kolumne
18.12.2018 - ifo-Geschäftsklimaindex fällt: Deutsche Wirtschaft ohne Rückenwind - VP Bank Kolumne
18.12.2018 - Gewerbliche Immobilien bleiben interessant - Commerzbank Kolumne
18.12.2018 - China 2019 mit niedrigster Wachstumsrate seit der globalen Finanzkrise - AXA IM Kolumne
18.12.2018 - DAX: Eisige Stimmung - Donner & Reuschel Kolumne
18.12.2018 - S&P 500: Wichtige Unterstützung erreicht - UBS Kolumne
18.12.2018 - DAX: Ein negativer Wochenauftakt - UBS Kolumne
17.12.2018 - Facebook Aktie: Reicht der Schwung? - UBS Kolumne

All Right Reserved by minimalthemes - ©2018 Stoffels & Barck GbR